SE0400235D0 - New composition containing quinoline compounds - Google Patents

New composition containing quinoline compounds

Info

Publication number
SE0400235D0
SE0400235D0 SE0400235A SE0400235A SE0400235D0 SE 0400235 D0 SE0400235 D0 SE 0400235D0 SE 0400235 A SE0400235 A SE 0400235A SE 0400235 A SE0400235 A SE 0400235A SE 0400235 D0 SE0400235 D0 SE 0400235D0
Authority
SE
Sweden
Prior art keywords
salt
formula
composition containing
new composition
quinoline compounds
Prior art date
Application number
SE0400235A
Other languages
English (en)
Swedish (sv)
Inventor
Karl Jansson
Tomas Fristedt
Hans Waennman
Anders Bjoerk
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0400235A priority Critical patent/SE0400235D0/xx
Publication of SE0400235D0 publication Critical patent/SE0400235D0/xx
Priority to NZ548469A priority patent/NZ548469A/en
Priority to KR1020137000988A priority patent/KR101457463B1/ko
Priority to JP2006551857A priority patent/JP4864724B2/ja
Priority to AU2005210174A priority patent/AU2005210174B2/en
Priority to US11/050,441 priority patent/US7589208B2/en
Priority to KR1020127013996A priority patent/KR20120062029A/ko
Priority to CN2005800038879A priority patent/CN1980669B/zh
Priority to ZA200605619A priority patent/ZA200605619B/en
Priority to AP2006003674A priority patent/AP2395A/xx
Priority to PCT/EP2005/050485 priority patent/WO2005074899A2/en
Priority to EP05707942A priority patent/EP1720531B1/en
Priority to RU2006132070/04A priority patent/RU2339622C2/ru
Priority to PT05707942T priority patent/PT1720531E/pt
Priority to PL05707942T priority patent/PL1720531T3/pl
Priority to CA2552463A priority patent/CA2552463C/en
Priority to ES05707942T priority patent/ES2364754T3/es
Priority to BRPI0506906-8A priority patent/BRPI0506906B1/pt
Priority to KR1020067017639A priority patent/KR101189557B1/ko
Priority to DK05707942.8T priority patent/DK1720531T3/da
Priority to DE602005027445T priority patent/DE602005027445D1/de
Priority to AT05707942T priority patent/ATE505186T1/de
Priority to UAA200608964A priority patent/UA90463C2/ru
Priority to SI200531327T priority patent/SI1720531T1/sl
Priority to IL176255A priority patent/IL176255A/en
Priority to NO20063931A priority patent/NO337235B1/no
Priority to HK07111206.0A priority patent/HK1105866A1/xx
Priority to US12/405,413 priority patent/US8314124B2/en
Priority to CY20111100676T priority patent/CY1111697T1/el
Priority to US13/669,920 priority patent/US8754104B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE0400235A 2004-02-06 2004-02-06 New composition containing quinoline compounds SE0400235D0 (sv)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SE0400235A SE0400235D0 (sv) 2004-02-06 2004-02-06 New composition containing quinoline compounds
SI200531327T SI1720531T1 (sl) 2004-02-06 2005-02-04 Novi sestavki, ki vsebujejo kinolinske spojine
PL05707942T PL1720531T3 (pl) 2004-02-06 2005-02-04 Nowe kompozycje zawierające związki chinoliny
ES05707942T ES2364754T3 (es) 2004-02-06 2005-02-04 Nuevas composiciones que contienen compuestos de quinolina.
CA2552463A CA2552463C (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds
AU2005210174A AU2005210174B2 (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds
KR1020137000988A KR101457463B1 (ko) 2004-02-06 2005-02-04 퀴놀린 화합물을 포함하는 신규 조성물
KR1020127013996A KR20120062029A (ko) 2004-02-06 2005-02-04 퀴놀린 화합물을 포함하는 신규 조성물
CN2005800038879A CN1980669B (zh) 2004-02-06 2005-02-04 含喹啉化合物的新组合物
ZA200605619A ZA200605619B (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds
AP2006003674A AP2395A (en) 2004-02-06 2005-02-04 New composition containing quinoline compounds.
PCT/EP2005/050485 WO2005074899A2 (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds
EP05707942A EP1720531B1 (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds
BRPI0506906-8A BRPI0506906B1 (pt) 2004-02-06 2005-02-04 Composição farmacêutica sólida estável contendo sal de um derivado de 3-quinolinacarboxamida, e processos para a estabilização de um sal, e para a preparação de um sal cristalino
PT05707942T PT1720531E (pt) 2004-02-06 2005-02-04 Novas composições contendo compostos de quinolina
NZ548469A NZ548469A (en) 2004-02-06 2005-02-04 Solid pharmaceutical formulation containing a salt of a 3-quinoline carboxamide derivative
JP2006551857A JP4864724B2 (ja) 2004-02-06 2005-02-04 キノリン化合物を含有する新規な組成物
US11/050,441 US7589208B2 (en) 2004-02-06 2005-02-04 Compositions containing quinoline compounds
RU2006132070/04A RU2339622C2 (ru) 2004-02-06 2005-02-04 Новые композиции, содержащие хинолиновые соединения
KR1020067017639A KR101189557B1 (ko) 2004-02-06 2005-02-04 퀴놀린 화합물을 포함하는 신규 조성물
DK05707942.8T DK1720531T3 (da) 2004-02-06 2005-02-04 Nye sammensætninger indeholdende quinolinforbindelser
DE602005027445T DE602005027445D1 (de) 2004-02-06 2005-02-04 Neue zusammensetzungen mit chinolin-verbindungen
AT05707942T ATE505186T1 (de) 2004-02-06 2005-02-04 Neue zusammensetzungen mit chinolin-verbindungen
UAA200608964A UA90463C2 (ru) 2004-02-06 2005-02-04 Композиция, содержащая соединения хинолина
IL176255A IL176255A (en) 2004-02-06 2006-06-12 New preparations containing quinoline compounds
NO20063931A NO337235B1 (no) 2004-02-06 2006-09-04 Nye sammensetninger inneholdende kinolinforbindelser
HK07111206.0A HK1105866A1 (en) 2004-02-06 2007-10-17 New compositions containing quinoline compounds
US12/405,413 US8314124B2 (en) 2004-02-06 2009-03-17 Crystalline salts of quinoline compounds and methods for preparing them
CY20111100676T CY1111697T1 (el) 2004-02-06 2011-07-12 Νεες συνθεσεις οι οποιες περιεχουν ενωσεις κινολινης
US13/669,920 US8754104B2 (en) 2004-02-06 2012-11-06 Crystalline salts of quinoline compounds and methods for preparing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400235A SE0400235D0 (sv) 2004-02-06 2004-02-06 New composition containing quinoline compounds

Publications (1)

Publication Number Publication Date
SE0400235D0 true SE0400235D0 (sv) 2004-02-06

Family

ID=31885235

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0400235A SE0400235D0 (sv) 2004-02-06 2004-02-06 New composition containing quinoline compounds

Country Status (26)

Country Link
US (1) US7589208B2 (xx)
EP (1) EP1720531B1 (xx)
JP (1) JP4864724B2 (xx)
KR (3) KR101457463B1 (xx)
CN (1) CN1980669B (xx)
AP (1) AP2395A (xx)
AT (1) ATE505186T1 (xx)
AU (1) AU2005210174B2 (xx)
BR (1) BRPI0506906B1 (xx)
CA (1) CA2552463C (xx)
CY (1) CY1111697T1 (xx)
DE (1) DE602005027445D1 (xx)
DK (1) DK1720531T3 (xx)
ES (1) ES2364754T3 (xx)
HK (1) HK1105866A1 (xx)
IL (1) IL176255A (xx)
NO (1) NO337235B1 (xx)
NZ (1) NZ548469A (xx)
PL (1) PL1720531T3 (xx)
PT (1) PT1720531E (xx)
RU (1) RU2339622C2 (xx)
SE (1) SE0400235D0 (xx)
SI (1) SI1720531T1 (xx)
UA (1) UA90463C2 (xx)
WO (1) WO2005074899A2 (xx)
ZA (1) ZA200605619B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
EA011862B1 (ru) * 2004-03-24 2009-06-30 Актавис Груп Хф. Композиции рамиприла
EP2489659B1 (en) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CA2625287C (en) 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
AU2013201426B2 (en) * 2005-12-28 2016-06-02 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2016219571B2 (en) * 2005-12-28 2018-03-15 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2790700T3 (es) 2005-12-28 2020-10-28 Vertex Pharma Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida
ZA200810790B (en) * 2006-06-12 2010-03-31 Teva Pharma Stable laquinimod preparations
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
EP2213305A4 (en) * 2007-11-27 2010-11-17 Ohara Pharmaceutical Co Ltd PROCESS FOR PRODUCING A PELLET SUBSTANCE
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8354428B2 (en) * 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
KR20160079147A (ko) * 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
NZ623264A (en) * 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
DE102008064379A1 (de) * 2008-12-22 2010-07-15 Siemens Aktiengesellschaft Magnetspulenanordnung mit festen und beweglichen Spulen
BRPI1011506B8 (pt) 2009-03-20 2021-05-25 Vertex Pharma processo para a fabricação de moduladores de regulador de condutância de transmembrana de fibrose cística
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法
SI2442651T1 (sl) * 2009-06-19 2015-10-30 Teva Pharmaceutical Industries Ltd. Zdravljenje multiple skleroze z lakvinimodom
MX2012001333A (es) * 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
ES2586843T3 (es) 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Tratamiento de trastornos relacionados con BDNF usando laquinimod
WO2011086470A1 (en) 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
WO2011089623A2 (en) * 2010-01-20 2011-07-28 Cadila Healthcare Limited Process for preparing pitavastatin and pharmaceutically acceptable salts thereof
PL2542080T3 (pl) * 2010-03-03 2017-02-28 Teva Pharmaceutical Industries Ltd. Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu
AU2011223692A1 (en) 2010-03-03 2012-10-25 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
SI2542079T1 (sl) * 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
PE20130246A1 (es) * 2010-03-23 2013-04-07 Vifor Int Ag COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SINTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
EA025377B1 (ru) * 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
MX2013000332A (es) 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
CN103153959A (zh) 2010-10-14 2013-06-12 伊姆纳尔公司 作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类
ES2548407T3 (es) 2011-05-31 2015-10-16 Vifor (International) Ag Compuestos de complejos de 2,4-dioxo-1-carbonilo de Fe(III) para su uso en el tratamiento y la profilaxis de estados de deficiencia de hierro y anemias por deficiencia de hierro
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
JP6215238B2 (ja) * 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
ES2658818T3 (es) 2012-12-21 2018-03-12 Vifor (International) Ag Compuestos del complejo FE(III) para el tratamiento y la profilaxis de síntomas asociados a deficiencia de hierro y de anemias ferropénicas
JP2016513665A (ja) 2013-03-14 2016-05-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドの経皮製剤
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
CA2961978C (en) 2014-09-23 2023-03-14 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
PL3180005T3 (pl) 2014-11-19 2018-06-29 Active Biotech Ab Chinolinokarboksyamidy do stosowania w leczeniu białaczki
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
KR20180065223A (ko) 2016-12-07 2018-06-18 순천향대학교 산학협력단 천식의 치료 또는 완화용 약학 조성물
AU2019322564A1 (en) 2018-08-15 2021-03-25 Pharmacyl Ab A new medical treatment for pathologic inflammation
BR112021001966A2 (pt) 2018-08-15 2021-04-27 Pharmacyl Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença resultante de inflamação patológica
EP4153576A4 (en) * 2020-05-21 2024-06-19 Stemsynergy Therapeutics Inc NOTCH INHIBITORS AND USES THEREOF
JP2023535021A (ja) 2020-07-23 2023-08-15 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質
CA3204120A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5077851A (en) * 1989-02-27 1992-01-07 Guma Juan M Method and apparatus for treating corded fabrics
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
RU2142790C1 (ru) * 1995-12-22 1999-12-20 Кова Компани Лтд Фармацевтическая композиция, стабилизированная основным агентом
AU2446297A (en) * 1996-04-30 1997-11-19 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
RS51019B (sr) * 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives

Also Published As

Publication number Publication date
KR101457463B1 (ko) 2014-11-04
JP4864724B2 (ja) 2012-02-01
WO2005074899A2 (en) 2005-08-18
AU2005210174B2 (en) 2010-10-07
NZ548469A (en) 2010-05-28
BRPI0506906A (pt) 2007-05-29
RU2006132070A (ru) 2008-03-20
IL176255A0 (en) 2006-10-05
KR101189557B1 (ko) 2012-10-12
NO337235B1 (no) 2016-02-15
DE602005027445D1 (de) 2011-05-26
CA2552463A1 (en) 2005-08-18
WO2005074899A3 (en) 2007-04-19
KR20130012084A (ko) 2013-01-31
AP2006003674A0 (en) 2006-08-31
JP2007520529A (ja) 2007-07-26
HK1105866A1 (en) 2008-02-29
ATE505186T1 (de) 2011-04-15
US20050192315A1 (en) 2005-09-01
ZA200605619B (en) 2007-11-28
KR20060130191A (ko) 2006-12-18
BRPI0506906B1 (pt) 2018-05-15
UA90463C2 (ru) 2010-05-11
AU2005210174A1 (en) 2005-08-18
SI1720531T1 (sl) 2011-08-31
IL176255A (en) 2011-11-30
CY1111697T1 (el) 2015-10-07
US7589208B2 (en) 2009-09-15
CN1980669A (zh) 2007-06-13
AP2395A (en) 2012-04-10
ES2364754T3 (es) 2011-09-13
RU2339622C2 (ru) 2008-11-27
NO20063931L (no) 2006-09-04
PL1720531T3 (pl) 2011-09-30
EP1720531B1 (en) 2011-04-13
EP1720531A2 (en) 2006-11-15
KR20120062029A (ko) 2012-06-13
DK1720531T3 (da) 2011-08-01
PT1720531E (pt) 2011-06-27
CA2552463C (en) 2013-05-14
CN1980669B (zh) 2011-11-30

Similar Documents

Publication Publication Date Title
SE0400235D0 (sv) New composition containing quinoline compounds
IL278766B2 (en) Molecule, N-(3-chloro-1-(pyridin-3-yl)-H1-pyrazol-4-yl)-2-(methylsulfonyl)propanamide, for use in pest control
MXPA03011039A (es) Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MXPA04002647A (es) Antranilamidas artropodicidas.
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
WO2005021519A3 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20054852L (no) GFAT inhibitorer
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2009005616A (es) Derivados de pirido-pirazina utiles como compuestos herbicidas.
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
UA99494C2 (ru) Производные пиридазинона, гербицидные композиции и способ контролирования роста нежелательной растительности
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
SE0202463D0 (sv) Novel compounds
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
TW200745063A (en) Triazolone derivatives
TW200744589A (en) Pharmaceutical composition
BRPI0407841A (pt) inibidores heterocìclicos de quinase
SE0302756D0 (sv) Novel Compounds
TW200730507A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
TW200510395A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor